Vicore initiates clinical proof-of-concept study of endothelial dysfunction
Stockholm, May 3, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), today announces the first patient dosed with C21 in a clinical study of endothelial dysfunction.
- Endothelial dysfunction is a key driver of organ damage associated with many diseases
- Vicore’s ATRAGs have properties suggesting that they may restore endothelial function
- Restoration of endothelial function may be both therapeutic and serve as an early efficacy biomarker in pulmonary, renal, vascular and several other diseases